HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial

作者：Carolina Porras, Byron Romero, Troy J. Kemp, Romain Fantin, Rolando Herrero, Allan Hildesheim, Rebeca Ocampo, Mónica S. Sierra, Mitchell H. Gail, John Schussler, John T. Schiller, Douglas R. Lowy, Lígia A. Pinto, Danping Liu, Aimée R Kreimer, Costa Rica HPV Vaccine Trial Study Group, Bernal Cortés, Paula González, Rolando Herrero, Silvia E. Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R Kreimer, Douglas R. Lowy, Mark Schiffman, John T. Schiller, Mark E. Sherman, Sholom Wacholder, Ligia A. Pinto, Troy J. Kemp, Mary Sidawy, Wim Quint, Leen‐Jan van Doorn, Linda Struijk, Joel M. Palefsky, Teresa M. Darragh, Mark H. Stoler · 发表于：JNCI Monographs · 年份：2024 · DOI：10.1093/jncimonographs/lgae032 · 被引用次数：32 · 研究领域：Cervical Cancer and HPV Research、Head and Neck Cancer Studies、Reproductive tract infections research

BACKGROUND: The Costa Rica HPV Vaccine Trial provided initial evidence that 1 dose of the bivalent human papillomavirus (HPV) vaccine induces stabilizing antibody levels that may provide extended protection against HPV-16/18 infections. We report antibody seropositivity and stability 11 to 16 years after vaccination. METHODS: We invited a random subset of Costa Rica HPV Vaccine Trial participants (n = 398) who had received 3 doses and all women (n = 203) who had received 1 dose at 18 to 25 years of age to follow-up visits 11, 14, and 16 years after vaccination. We calculated HPV-16 and HPV-18 seropositivity and assessed change in enzyme-linked immunosorbent assay antibody levels 11 to 16 years after vaccination among 500 participants. RESULTS: By year 16, 99.4% (95% confidence interval [CI] = 96.8% to 100.0%) and 100.0% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-16 seropositive and 98.8% (95% CI = 95.9% to 99.9%) and 100% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-18 seropositive. Between years 11 and 16, women who had received 3 doses had a small but statistically significant decrease in the geometric mean concentration for HPV-16 of ‒12.4% (95% CI = ‒16.3% to ‒8.4%) and HPV-18 of ‒13.4% (95% CI = ‒17.2% to ‒9.4%). Among women who had received 1 dose, the decrease was statistically significant for HPV-16 at ‒8.9 (95% CI = ‒14.2% to ‒3.1%) but nonsignificant for HPV-18. Geometric mean concentratio...